Profile data is unavailable for this security.
About the company
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
- Revenue in USD (TTM)70.00m
- Net income in USD21.50m
- Incorporated2014
- Employees24.00
- LocationBlack Diamond Therapeutics Inc245 First Street, 18Th FloorCAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 417-5868
- Fax+1 (302) 655-5049
- Websitehttps://www.blackdiamondtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coya Therapeutics Inc | 3.99m | -18.43m | 115.59m | 8.00 | -- | 3.03 | -- | 28.99 | -1.11 | -1.11 | 0.2397 | 1.63 | 0.118 | -- | -- | 498,462.50 | -54.54 | -- | -59.84 | -- | -- | -- | -462.26 | -- | -- | -- | 0.00 | -- | -40.79 | -- | -86.29 | -- | -- | -- |
| Korro Bio Inc | 7.37m | -88.42m | 115.74m | 87.00 | -- | 1.17 | -- | 15.70 | -9.42 | -9.42 | 0.7855 | 10.54 | 0.0364 | -- | 1.36 | 70,875.00 | -43.65 | -- | -46.92 | -- | -- | -- | -1,199.53 | -- | -- | -- | 0.00 | -- | -- | -- | -2.97 | -- | -- | -- |
| AVITA Medical Inc | 72.40m | -48.56m | 117.09m | 260.00 | -- | -- | -- | 1.62 | -1.81 | -1.81 | 2.70 | -0.2186 | 1.00 | 1.63 | 7.50 | 278,461.50 | -67.07 | -- | -147.57 | -- | 84.81 | -- | -67.06 | -- | 0.5519 | -8.20 | 1.19 | -- | 28.14 | -- | -74.80 | -- | -- | -- |
| Black Diamond Therapeutics Inc | 70.00m | 21.50m | 126.48m | 24.00 | 6.12 | 1.00 | 5.79 | 1.81 | 0.3629 | 0.3629 | 1.23 | 2.22 | 0.4736 | -- | -- | 2,916,667.00 | 14.54 | -42.24 | 16.58 | -46.05 | -- | -- | 30.71 | -- | -- | -- | 0.00 | -- | -- | -- | 15.48 | -- | -- | -- |
| Seres Therapeutics Inc | 351.00k | 5.39m | 127.47m | 103.00 | 23.92 | 2.83 | 13.20 | 363.15 | 0.5892 | 0.5892 | 0.0404 | 4.99 | 0.0022 | -- | -- | 3,407.77 | 3.35 | -42.44 | 4.59 | -55.22 | -- | -- | 1,536.75 | -367.23 | -- | -- | 0.00 | -- | -- | -- | 33.85 | -- | -17.63 | -- |
| Oramed Pharmaceuticals, Inc. | 2.00m | 43.85m | 129.36m | 13.00 | 3.23 | 0.6529 | 2.94 | 64.68 | 1.01 | 1.01 | 0.0478 | 4.98 | 0.0104 | -- | -- | 153,846.20 | 22.72 | -- | 23.30 | -- | 0.65 | -- | 2,190.40 | -- | -- | -- | 0.00 | -- | -100.00 | -- | -444.98 | -- | -- | -- |
| Prelude Therapeutics Inc | 10.50m | -111.77m | 131.39m | 131.00 | -- | 2.02 | -- | 12.51 | -1.47 | -1.47 | 0.1382 | 1.03 | 0.0719 | -- | -- | 80,152.67 | -76.56 | -47.36 | -88.86 | -51.44 | -- | -- | -1,064.50 | -7,615.23 | -- | -- | 0.00 | -- | -- | -- | -4.38 | -- | -0.4137 | -- |
| Spero Therapeutics Inc | 40.55m | -43.84m | 133.52m | 32.00 | -- | 5.04 | -- | 3.29 | -0.7949 | -0.7949 | 0.7299 | 0.4705 | 0.4283 | -- | 1.45 | 1,267,156.00 | -46.31 | -35.16 | -69.26 | -42.63 | -- | -- | -108.11 | -111.75 | -- | -- | 0.00 | -- | -53.77 | 21.46 | -400.65 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -67.51m | 133.75m | 28.00 | -- | 1.04 | -- | -- | -5.51 | -5.51 | 0.00 | 7.35 | 0.00 | -- | -- | 0.00 | -49.34 | -69.78 | -55.11 | -97.84 | -- | -- | -- | -5,894.85 | -- | -- | 0.00 | -- | -- | -- | 9.85 | -- | -- | -- |
| Microbot Medical Inc | 0.00 | -13.07m | 134.32m | 21.00 | -- | 1.68 | -- | -- | -0.4513 | -0.4513 | 0.00 | 1.19 | 0.00 | -- | -- | 0.00 | -30.06 | -67.69 | -31.62 | -80.15 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.55 | -- | -35.03 | -- |
| Unicycive Therapeutics Inc | 0.00 | -33.47m | 134.32m | 22.00 | -- | 3.48 | -- | -- | -2.85 | -2.85 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -74.93 | -188.44 | -101.88 | -723.53 | -- | -- | -- | -6,003.20 | -- | -- | 0.00 | -- | -100.00 | -- | -20.42 | -- | -- | -- |
| ALX Oncology Holdings Inc | 0.00 | -108.01m | 134.46m | 44.00 | -- | 2.97 | -- | -- | -2.01 | -2.01 | 0.00 | 0.8362 | 0.00 | -- | -- | 0.00 | -80.47 | -37.96 | -103.67 | -40.71 | -- | -- | -- | -46,390.86 | -- | -- | 0.2099 | -- | -- | -- | 16.14 | -- | 4.84 | -- |
| Fate Therapeutics Inc | 7.14m | -156.09m | 134.96m | 181.00 | -- | 0.5765 | -- | 18.91 | -1.32 | -1.32 | 0.0603 | 2.03 | 0.017 | -- | 2.30 | 39,430.94 | -37.23 | -32.44 | -40.38 | -36.57 | -- | -- | -2,187.11 | -389.06 | -- | -- | 0.00 | -- | -78.55 | 5.00 | -15.74 | -- | -37.07 | -- |
| vTv Therapeutics Inc | 17.00k | -23.47m | 135.44m | 23.00 | -- | 1.92 | -- | 7,966.87 | -3.32 | -3.32 | 0.0024 | 17.91 | 0.0002 | -- | -- | 739.13 | -39.79 | -96.30 | -46.08 | -- | -- | -- | -166,935.30 | -775.06 | -- | -- | 0.0046 | -- | -- | -18.12 | 8.83 | -- | -- | -- |
| Vaxart Inc | 148.20m | -50.70m | 137.97m | 105.00 | -- | 4.92 | -- | 0.9309 | -0.2222 | -0.2222 | 0.6495 | 0.1169 | 0.789 | -- | 3.31 | 1,411,467.00 | -26.99 | -49.90 | -80.48 | -58.33 | -- | -- | -34.21 | -875.06 | -- | -31.43 | 0.1161 | -- | 288.94 | 23.82 | 18.82 | -- | -8.21 | -- |
| HST Global Inc | 0.00 | -212.63k | 139.70m | 1.00 | -- | 8.48 | -- | -- | -0.0107 | -0.0107 | 0.00 | 0.1167 | 0.00 | -- | -- | -- | -6.87 | -27.80 | -8.09 | -60.19 | -- | -- | -- | -- | -- | -107.48 | 0.0433 | -- | -- | -- | -45.42 | -- | -- | -- |
Data as of Feb 12 2026. Currency figures normalised to Black Diamond Therapeutics Inc's reporting currency: US Dollar USD
43.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2025 | 10.74m | 18.86% |
| Vestal Point Capital LPas of 30 Sep 2025 | 5.55m | 9.74% |
| Tang Capital Management LLCas of 30 Sep 2025 | 2.07m | 3.63% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.91m | 3.36% |
| Marshall Wace LLPas of 30 Sep 2025 | 1.30m | 2.28% |
| Arrowstreet Capital LPas of 30 Sep 2025 | 896.85k | 1.57% |
| Millennium Management LLCas of 30 Sep 2025 | 850.33k | 1.49% |
| AWM Investment Co., Inc.as of 30 Sep 2025 | 600.00k | 1.05% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 599.40k | 1.05% |
| BlackRock Advisors LLCas of 30 Sep 2025 | 504.98k | 0.89% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
